Malignant Neoplasms of Digestive Organs Clinical Trial
Official title:
Chimeric Antigen Receptor T Cells (CART) Therapy in GUCY2C Positive Digestive System Tumors
Chimeric Antigen Receptor T Cells (CART) Therapy in GUYC2C postive Digestive system tumors, include colorectal cancer, gastric cancer, liver cancer, pancreatic cancer, adenocarcinoma of esophagus, cancer of the esophagogastric junction. Ict-gc is an open, single-center study to evaluate the safety and efficacy of CAR-T-targeted therapy in patients with advanced gastrointestinal tumors.
The primary objective of phase 1 is to evaluate the safety of CART regimens. The primary objective of phase 2 is to evaluate the efficacy of CART, as measured by objective response rate in subjects with colorectal cancer. Secondary objectives will include assessing the safety and tolerability of CART and additional efficacy endpoints. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02812056 -
Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
|
Phase 1 | |
| Completed |
NCT04652219 -
CART Therapy in GUCY2C-positive Digestive Tract Tumors
|
Early Phase 1 | |
| Completed |
NCT03210376 -
Neuromuscular Blockade on Shoulder Pain of Elderly
|
Phase 4 | |
| Completed |
NCT03428126 -
Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03435952 -
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
|
Phase 1 | |
| Withdrawn |
NCT02915172 -
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT03162627 -
Selumetinib and Olaparib in Solid Tumors
|
Phase 1 |